145202-66-0CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1JPRXYLQNJJVCMZ-UHFFFAOYSA-NRizatriptan benzoate is a member of tryptamines.
145202-66-0DTXSID20162937FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H302 (35.6%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P304+P340, P305+P351+P338, P318, P319, P330, P337+P317, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 149 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Rizatriptan benzoate
vLess-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
RIZATRIPTAN BENZOATE
Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]; Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
RIZATRIPTAN BENZOATE ODT
Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]; Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]
BeschreibungRizatriptan was launched for the first time as Maxalt in Mexico for the acute treatment of migraine headaches with or without aura in adults. It is the third in a new generation of triptan migraine drugs to challenge the firstgeneration product Sumatriptan from Glaxo Wellcome, after Zolmitriptan (Zeneca) and Naratriptan (Glaxo Wellcome). It can be synthetically obtained by two related routes having respectively 3 and 4 steps, both starting from 1 -(4-aminobenzyl)-l,2,4-triazole. Rizatriptan is a full 5-HT1D/1B receptor agonist retaining a significant affinity at 5-HT1A sites (pIC50 = 6.4), with a low affinity for nond-HT sites. It shows craniovascufar selectivity for human isolated middle meningeal over coronary arteries ; its effect on coronary artery constriction is significantly less than that for Sumatriptan. Rizatriptan inhibits the release of neuropeptides that cause swelling of cranial blood vessels. Rizatriptan has a good oral bioavailability (64% and 47% in rats and dogs respectively). and a rapid onset of action : the headache relief in human occurs within 30 to 45 minutes of taking 20 mg. It also relieved nausea and hypersensitivity to noise (phonophobia) and light (photophobia) that are often symptoms accompanying a migraine attack. Among at least 6 metabolites identified in humans after a single oral dose (60 mg), the major urinary metabolite was the corresponding indole-3-acetic acid. Maxalt is available as a novel oral formulation of rapidly dissolving tablets or wafers that does not require liquid for ingestion.
CHEMBL1201032CHEBI:8875VerwendenRizatriptan Benzoate is a selective serotonin 5-HTID receptor agonist and used to treat migraine (1,2,3). It is structurally derived from tryptamine.